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SUMMARY
While the catalog of mammalian transcripts and their expression levels in different cell types and 
disease states is rapidly expanding, our understanding of transcript function lags behind. We 
present a robust technology enabling systematic investigation of the cellular consequences of 
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repressing or inducing individual transcripts. We identify rules for specific targeting of 
transcriptional repressors (CRISPRi), typically achieving 90–99% knockdown with minimal off-
target effects, and activators (CRISPRa) to endogenous genes via endonuclease-deficient Cas9. 
Together they enable modulation of gene expression over a ~1000-fold range. Using these rules, 
we construct genome-scale CRISPRi and CRISPRa libraries, each of which we validate with two 
pooled screens. Growth-based screens identify essential genes, tumor suppressors and regulators 
of differentiation. Screens for sensitivity to a cholera-diphtheria toxin provide broad insights into 
the mechanisms of pathogen entry, retro-translocation and toxicity. Our results establish CRISPRi 
and CRISPRa as powerful tools that provide rich and complementary information for mapping 
complex pathways.
INTRODUCTION
Dramatic advances in sequencing technology have catalogued a universe of transcribed loci
—greatly exceeding the number of canonical protein-coding open reading frames (ORFs)—
which collectively are responsible for carrying out the instructions encoded by the genome 
(Djebali et al., 2012). A central challenge now is to understand the biological role of these 
transcripts and how quantitative differences in their expression define cellular states in 
normal development and in disease. Despite intense efforts, the function of many protein-
coding genes remains poorly defined. Even less is known about the biological roles of most 
non-canonical transcripts such as enhancer RNAs, upstream antisense RNAs, lncRNAs, or 
other intergenic RNAs (Cech and Steitz, 2014). Efforts to address this deficiency in our 
knowledge would be greatly aided by techniques that are capable of dynamically and 
precisely controlling the expression of individual transcripts.
One way to explore the function of genes is to disrupt their expression through repression. 
The dominant tool for programmed knockdown of mRNAs is RNA interference (RNAi) 
(Chang et al., 2006). However, RNAi has pervasive problems with off-target effects, which 
can be especially confounding in the context of large-scale screens (Adamson et al., 2012; 
Jackson et al., 2003; Sigoillot et al., 2012). Additionally, because RNAi is mediated by 
cytoplasmic argounaute proteins, gene silencing through this approach is best suited to 
depletion of cytosolic mRNA targets.
An alternative emerging strategy is the use of programmable genome editing methods that 
permanently delete or modify DNA using designable, sequence-specific endonucleases such 
as zinc finger, transcription activator-like effector (TALE) nucleases, or CRISPR (clustered 
regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) 
proteins (Gaj et al., 2013; Sander and Joung, 2014). A series of elegant studies recently 
exploited the readily programmable nature of Cas9, in which the specificity is determined by 
a short guide (sg)RNA, to enable genome-scale loss-of-function screens (Koike-Yusa et al., 
2014; Shalem et al., 2014; Wang et al., 2014). These studies established CRISPR-mediated 
cutting as a powerful screening technology complementary to RNAi and haploid 
mutagenesis screens (Carette et al., 2009). Nonetheless, screening approaches based on 
genome editing are currently focused on loss-of-function studies involving irreversible 
frameshift disruptions, limiting their utility for the study of essential genes and long 
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noncoding RNAs. Additionally, double-stranded DNA breaks can be cytotoxic (Huang et 
al., 1996; Jackson, 2002). Finally, indels formed from error-prone DNA repair are often 
short and in-frame, which could limit the ability to disable all of the alleles of a gene.
A programmable DNA binding protein that can recruit an effector domain to turn 
transcription on and off in a dynamic and quantitative manner offers, in principle, a more 
flexible tool for interrogating the many transcripts in complex genomes. Pioneering 
experiments with designed chimeric zinc finger and TALE proteins fused to transcription 
effector domains demonstrate that such an approach can modulate transcription of 
endogenous genes (Beerli et al., 1998, 2000; Zhang et al., 2011). However, as each 
transcript target requires a unique fusion protein, expanding these methods to genome-scale 
is arduous.
Recently, we and others have used catalytically inactive Cas9 (dCas9) fusion proteins 
guided by gene-specific sgRNAs to localize effector domains to specific DNA sequences to 
either repress (CRISPRi) or activate (CRISPRa) transcription of target genes (Gilbert et al., 
2013; Sander and Joung, 2014). To date, a small number of sgRNAs have been tested, 
leaving unanswered whether CRISPRi/a is a feasible strategy for globally interrogating gene 
function and, if so, how best to target a gene to activate or repress transcription while 
minimizing off-target effects.
Here, we describe the development and application of a method for high-specificity, 
genome-scale modulation of transcription of endogenous genes in human cells using 
CRISPRi/a. To accomplish this, we first performed a saturating screen in which we tested 
the activity of every unique sgRNA broadly tiling around the transcription start sites (TSSs) 
of 49 genes known to modulate cellular susceptibility to ricin (Bassik et al., 2013). From 
this, we extracted distinct rules for regions where either CRISPRi or CRISPRa maximally 
changes the expression of endogenous genes, as well as rules for predicting off-target 
effects, providing an algorithm to design two genome-scale libraries targeting each gene 
with 10 sgRNAs. We validated these libraries by screening for genes that control cell growth 
and response to a chimeric cholera/diphtheria fusion toxin (CTx-DTA) (Guimaraes et al., 
2011). These experiments demonstrate that our CRISPRi/a screening platform is robust, 
showing high reproducibility and activity with undetectable intrinsic toxicity. More 
generally, we establish that transcriptional repression is inducible, reversible, and can target 
essential genes. We demonstrate that we can use CRISPRi and CRISPRa to control 
transcript levels for endogenous genes across a high dynamic range. We also provide 
extensive evidence that properly designed CRISPRi reagents are highly specific. As such, 
these methods represent transformative tools for defining transcript function across the 
breadth of transcripts encoded by the human genome.
RESULTS
A High-Throughput Tiling Screen Defines Rules for CRISPRi Activity at Endogenous 
Genes
CRISPRi can repress transcription by directly blocking RNA polymerase activity (dCas9) or 
through effector domain-mediated transcriptional silencing (dCas9-KRAB) (Gilbert et al., 
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2013; Qi et al., 2013). In order to better understand and optimize CRISPRi activity, we used 
a pooled high-throughput screen to define rules that determine CRISPRi repression of 
endogenous genes. We targeted 49 genes that we had previously shown to modulate cellular 
susceptibility to the AB toxin ricin (Bassik et al., 2013). The extent of gene repression for 
these genes typically has a monotonic relationship with the ricin resistance phenotype, 
allowing us to use a ricin resistance score calculated by monitoring sgRNA frequencies in a 
pooled screen to indirectly measure transcriptional repression.
Using massively parallel oligonucleotide synthesis, we generated a library of sgRNAs that 
tile the DNA in a 10-kilobase window around the TSS of these 49 genes (54,810 total 
sgRNAs) (Bassik et al., 2009) (Figure 1A). We also included 1,000 negative control 
sgRNAs derived from scrambled sequences corresponding to the same windows.
We packaged this tiling library of sgRNAs into lentiviral particles and transduced K562 
human myeloid leukemia cells stably expressing dCas9 or a dCas9-KRAB fusion protein, 
which we have previously described (Gilbert et al., 2013). We harvested populations of cells 
expressing the library either at the outset of the experiment, after growth under standard 
conditions, or following ricin treatment. We then counted the frequency of each sgRNA in 
the library in each sample using deep sequencing to determine how each sgRNA in the 
library modulates cell growth and cellular susceptibility to ricin phenotypes. We defined 
these phenotypes quantitatively as gamma (γ) and rho (ρ), respectively (See Figure S1A and 
(Kampmann et al., 2013)).
Many sgRNAs potently repress gene expression, as evidenced by their impact on ricin 
sensitivity (Figure 1B and Figure S2A). Plotting this data for all 49 genes showed that active 
sgRNAs cluster around or just downstream from the TSS of each gene for dCas9-KRAB and 
dCas9, respectively (Figure 1C). We saw that strong CRISPRi activity is obtained by 
targeting dCas9-KRAB to a window of DNA from −50 to +300 bp relative to the TSS of a 
gene, with a maximum in the ~50–100 bp region just downstream of the TSS (Figure 1C–
D). This suggested that optimal activity leverages the combined activity of dCas9 
interference along with repression from the KRAB domain. We also observed that sgRNAs 
with protospacer lengths of 18–21 base pairs were significantly more active than sgRNAs 
containing longer protospacers (Figure S2B). Nucleotide homopolymers had a strongly 
negative effect on sgRNA activity (Figure S2D). However, neither the DNA strand that was 
targeted nor the sgRNA GC content across a broad range strongly correlated with sgRNA 
activity (Figure S2C and S2E).
To evaluate the feasibility of genome-scale genetic screens based on CRISPRi, we compared 
the strength of phenotypes obtained with CRISPRi to our previously published shRNA data. 
We applied the rules described above to randomly subsampled data from our sgRNA tiling 
library, picking sets of 10 or 24 sgRNAs. We calculated a normalized phenotype z-score by 
dividing mean phenotypes for each gene by the standard deviation of sgRNA phenotypes 
from the non-targeting control set (Figure S1B). We see significant ricin phenotypes for 
each of the 49 genes. Moreover, in virtually every case the normalized ricin phenotype z-
score or p-value is stronger (in many cases far stronger) than seen with a comparably-sized 
shRNA library (generated by sub-sampling our published data) (Figure 1E and Figure S2F).
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CRISPRi Transcriptional Silencing is Highly Sensitive to Mismatches between the Target 
DNA Site and the sgRNA
To assess CRISPRi off-target activity at endogenous genes, we selected a set of 30 sgRNAs 
from our tiling library (6 sgRNAs/gene targeting 5 genes). For each of these sgRNAs, we 
tested the activity of a series of derivative sgRNAs with a variable number and position of 
mismatches (Figure 2). This experiment allowed us to measure the relative amount of gene 
repression for sgRNAs with or without mismatch base pairing targeting the same DNA 
locus. We found that even a single mismatch at the 3′ end of the protospacer decreased 
CRISPRi activity on average, while combinations of mismatches that pass our off-target 
filter abolished activity (Figure 2, Figure S3, and Extended Experimental Procedures). From 
this analysis, we concluded that properly designed CRISPRi sgRNAs have minimal off-
target transcriptional repression activity.
A High-Throughput Tiling Screen Defines Rules for CRISPRa Activity at Endogenous 
Genes
We recently developed an improved CRISPRa method, termed sunCas9, in which 
expression of a single sgRNA with one binding site is sufficient to robustly activate 
transcription (Tanenbaum et al.) In the sunCas9 system, a single dCas9 fusion protein bound 
to DNA recruits multiple copies of the activating effector domain, thus amplifying our 
ability to induce transcription (Figure 3A).
To define rules for optimal CRISPRa sgRNA design, we used our tiling library, which 
targets genes capable of modulating cellular sensitivity to ricin. We previously showed for 
several of the genes in this tiling library that knockdown and plasmid overexpression 
resulted in opposite ricin phenotypes (Bassik et al., 2013). For example, knockdown of 
SEC23B sensitized cells to ricin, whereas SEC23B overexpression desensitized cells to ricin. 
These observations suggested that we should be able to observe reversed phenotypes in this 
tiling screen arising from CRISPRa activity.
We transduced K562 cells stably expressing the sunCas9 system (Figure 3A) with the 
sgRNA tiling library and screened for ricin phenotypes as described for CRISPRi above. 
Analysis of data for individual genes or averaged data for all 49 genes demonstrated that 
many sgRNAs for each gene affected ricin resistance (Figure 3B and Figure S4A–B). Our 
negative control sgRNAs showed very little activity and were not correlated between 
biological replicate screens, suggesting that CRISPRa activity is specific. We observed a 
peak of active sgRNAs for CRISPRa at −400 to −50 bp upstream from the TSS (Figure 3B). 
This activity pattern fits with a model in which each VP16 domain can bind the mediator 
complex and recruit basal transcription machinery, activating transcription when spaced 
appropriately from a TSS (Mittler et al., 2003). With this system, we have shown we can 
turn on genes that are poorly expressed and increase the expression of well-expressed genes 
(Figure 3E). Overall, our CRISPRi/a tiling screens provide rules for how CRISPRi/a 
controls expression of endogenous genes.
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An Allelic CRISPRi/a Series of Transcript Activation and Repression Shows that Protein 
Abundance Dynamically Modulates the Cellular Response to Ricin
For many genes, we do not know how the relative abundance of the encoded protein relates 
to its function. We observed a marked anti-correlation in our ricin screens between 
CRISPRa phenotypes and CRISPRi phenotypes for individual genes (Figure 3C). As the 
genes targeted by our tiling library were selected based on a knockdown phenotype, all 
genes showed phenotypes in the CRISPRi screen, but only a subset showed phenotypes in 
the CRISPRa screen.
To validate results from both the CRISPRi and CRISPRa tiling screens, we selected an 
allelic series of sgRNAs by phenotype from the screen and re-tested each sgRNA 
individually (38 sgRNAs targeting 4 genes). Our results show that our CRISPRi/a screens 
produced reliable phenotype scores, robustly reproduced upon retesting, and that CRISPRi/a 
can activate and repress the transcription of endogenous genes over a wide dynamic range 
(up to ~1000-fold) (Figure 3D–E), enabling systematic interrogation of how gene dosage 
controls cellular functions of interest.
A Robust and Highly Specific Genome-Scale CRISPRi Screening Platform
The results of our tiling CRISPRi screen established our ability to pick active sgRNAs with 
low off-target activity and provided a set of rules enabling us to design a robust genome-
scale sgRNA library. We chose a library size of 10 sgRNAs/gene for the following reasons. 
Over half of the sgRNAs conforming to these rules gave clear ricin phenotypes. For a library 
with 10 sgRNAs/gene, 94% of the genes would thus have 2 or more highly active sgRNAs. 
Finally, computational sub-sampling of the phenotypic data from our tiling library data to 10 
sgRNAs/gene and calculation of z-scores for hit genes indicated that a library with 10 
sgRNAs/gene would reliably detect hit genes (Figure 1E).
We synthesized and cloned a genome-scale CRISPRi sgRNA library targeting 15,977, 
human protein-coding genes (10 sgRNAs/TSS, targeting 20,898 TSS) with 11,219 non-
targeting control sgRNAs for a total of 206,421 sgRNAs (Table S2). To evaluate this library, 
we first screened for genes essential for cell growth in K562 cells. Briefly, K562 cells stably 
expressing dCas9-KRAB were transduced in replicate with the entire genome-scale library, 
and each replicate was grown for 10 days at a minimum library coverage of 3,750 cells/
sgRNA in a single spinner flask.
To characterize our screening methodology and library design, we examined the correlation 
between screen replicates and our negative control distributions. Individual sgRNAs 
reproducibly showed dramatic depletion (up to 256-fold) over a 10-day screen, 
demonstrating that individual sgRNAs can have profound effects on cell growth (Table S2) 
(Figure 4A). The distribution of our negative-control sgRNAs was very narrow with little 
correlation between replicates (Spearman R = 0.036), suggesting that the off-target activity 
of these controls is very low (Figure 4A). Indeed, 99.7% of our negative controls had no 
detectable activity. The observed specificity is consistent with our previously published 
RNA-seq data (Gilbert et al., 2013).
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To further explore the prevalence of off-target effects, we examined two classes of genes not 
expected to show any on-target activity in our screen: olfactory receptors and genes on the Y 
chromosome. The sgRNAs that target these genes were designed and picked in the same 
manner as the rest of library; however, olfactory receptors should not be expressed in this 
cell type and, as K562 cells are derived from a female donor, sgRNAs that target genes on 
the Y chromosome lack a DNA target. As with the negative controls, these genes show no 
phenotype on average and exhibit very little correlation between replicates (Spearman R = 
0.057 for olfactory genes and −0.052 for Y-targeting) (Figure 4A). We also observed no 
evidence of non-specific toxicity due to expression of dCas9-KRAB and our sgRNA library 
in K562 cells suggesting that dCas9 bound to the genome is not toxic under these conditions 
(Figure 4B). Thus, CRISPRi is highly specific and non-toxic.
To identify hit genes in this screen, we used a metric of average growth phenotype (γ) for 
the top three sgRNAs for each gene (see Experimental Procedures and Table S3). Among 
the top hits were genes involved in essential cellular functions, including translation, 
transcription and DNA replication (Figure 4C and Figure S5A) (Huang et al., 2009a, 2009b), 
thus validating our approach as a screening platform.
A Genome-Scale CRISPRa Screening Platform
The results of our CRISPRa tiling screen established our ability to confidently measure gene 
phenotypes resulting from inducing expression with single sgRNAs. As with the CRISPRi 
tiling screens, our data enabled the development of a set of rules that allowed construction of 
a genome-scale CRISPRa library. Many of these rules overlapped with those of CRISPRi 
(e.g., sgRNA length and sequence preferences). A key difference is that the optimal window 
for targeting sgRNAs for CRISPRa lies upstream of the TSS (Figure 3B). We therefore 
constructed an independent CRISPRa library, designing 10 sgRNAs between 400 to 50 base 
pairs upstream of each TSS for 15,977 human genes, along with 5,968 non-targeting control 
sgRNAs, for a total of 198,810 sgRNAs.
We evaluated our CRISPRa platform in a screen for genes that affect cell growth when 
induced in K562 cells constitutively expressing the sunCas9 system. Replicate screens were 
conducted as described above. The magnitude of growth defects seen in our CRISPRa 
screen was comparable to that of the above CRISPRi screen, although fewer sgRNAs caused 
a growth phenotype (Figure S5B and Table S2). We analyzed control sgRNAs with no 
genomic target or Y chromosome targets and found minimal phenotypes, which lacked 
substantial correlation between experimental replicates (Spearman R = 0.155 and R = 0.010, 
respectively), indicating that the phenotype distribution observed in non-targeting controls 
was primarily a result of stochastic noise rather than off-target effects. Furthermore, the 
fraction of cells expressing sgRNAs and the sunCas9 system was stable over the course of 
the experiment, indicating that there was no general toxicity associated with the CRISPRa 
platform (Figure 4B). These data suggest that CRISPRa is also specific and non-toxic.
Defining Regulators of Survival and Differentiation in Human Cells by CRISPRa
We then investigated the genes whose induction caused cells to deplete over the course of 
our CRISPRa screen. We scored genes by the average γ of the three most active sgRNAs as 
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above, and compared these phenotypes to those observed in the CRISPRi screen (Figure 4D 
and Table S3). The results from the two screens had little overlap, suggesting that few genes 
are both essential and toxic upon induction, and that wild-type expression levels of genes are 
generally optimal for K562 growth. Whereas CRISPRi hits are naturally limited to 
expressed genes, CRISPRa hits included genes across a broad range of endogenous 
expression levels (Figure S5D). We observed that the majority of genes that inhibited 
growth in the CRISPRa screen fell into three overlapping classes.
The first class was tumor suppressor genes: 18 of the top 50 genes, including six of the top 
seven, are known to have potent tumor suppressor activity (Vogelstein et al., 2013; Zhao et 
al., 2013). These genes include p53-related protein TP73, cell cycle inhibitors CDKN1C 
(p57) and CDKN1A (p21), apoptotic factors BAK1 and BCL2L11 (BIM), and chromatin 
remodeling factor ARID1A (Figure 4D and Table S4). Gene set enrichment analysis (GSEA) 
confirmed this observation, highlighting several genes important in the intrinsic pathway of 
apoptosis or in chronic myeloid leukemia (CML) homeostasis consistent with the origin of 
K562 cells as a clonal isolate from a CML blast crisis (ATCC) (Figure 4E). Similarly, top 
gene ontology annotations included “positive regulation of apoptosis” and “regulation of cell 
cycle” (Figure S5C). While tumor suppressors are classically considered to be mutated early 
in cancer progression (Vogelstein et al., 2013), these results demonstrate than many 
potential tumor suppressor genes remain functional but down-regulated, and suggest that 
CRISPRa can be used to pinpoint intact pathways and vulnerabilities in tumor cells.
Transcription factor families with well-established roles in tissue development and 
differentiation represent another class of growth hits, accounting for 16 of the top 50 genes 
(K562 cells have known potential to undergo erythroid differentiation). These genes include 
CCAAT/Enhancer-binding proteins (CEBP), Homeobox genes, Forkhead box genes, Ikaros 
family zinc finger proteins, and hematopoietic differentiation factor SPI1 (PU.1) (Figure 4D 
and Table S4) (Spitz and Furlong, 2012). This observation is reflected in enriched 
annotations relating to multicellularity, cell differentiation, and development (Figure S5C).
The complementary nature of the CRISPRi and CRISPRa screens is nicely illustrated by 
results from two gene pairs (SPI1/GATA1 and CEBPA/CEBPG) in which one member of 
each pair inhibits the function of the other. GATA1 and CEBPG were strong hits in the 
CRISPRi screen, consistent with their roles as inhibitors of myeloid differentiation. By 
contrast, both SPI1 and CEBPA were robust hits in our CRISPRa activation screen. These 
observations are consistent with the inhibitory functions of SPI1 and CEBPA: silencing of 
CEBPA leads to de-repression of CEBPG (Alberich-Jordà et al., 2012) and the protein 
encoded by SPI1 (PU.1) is a direct binding partner of GATA-1 and inhibits its 
transcriptional activity (Zhang et al., 2000).
Finally, several hit genes have key roles in mitosis. PLK4 controls centrosome duplication, 
and overexpression of the gene in U2OS cells leads to increased centriole number 
(Habedanck et al., 2005). The proteins encoded by KIF18B and KIF2C form a complex that 
destabilizes microtubules during mitosis (Tanenbaum et al., 2011).
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Overall, the results from our paired CRISPRi/a growth screens demonstrate that 
complementary information can be obtained by loss- and gain-of-function genetic screens, 
and highlight the utility of the platform for future studies into tumor biology and cell 
differentiation.
Dynamically Controlling Gene Expression with CRISPRi
The ability to reversibly tune the expression of select transcripts would be a powerful tool 
for evaluating transcript function. To evaluate the applicability of CRISPRi to this purpose, 
we cloned a lentiviral expression construct that places an optimized KRAB-dCas9 fusion 
protein under the control of a doxycycline-inducible promoter (Figure 5A–B). Induced 
expression of KRAB-dCas9 robustly depletes transcript levels from sgRNA-targeted genes 
(Figure 5C and S5E). To further assess dynamic control of CRISPRi, we inducibly repressed 
several genes identified in our genome-scale CRISPRi growth screen (Figure S5G). Cells 
that express sgRNAs targeting these essential genes showed almost no growth phenotype in 
the absence of doxycycline, but rapidly and robustly disappeared from the population upon 
addition of doxycycline (Figure 5D). Additionally, gene repression and resulting phenotypes 
were reversible (Figure 5C and S5E–F), indicating that KRAB-dCas9 does not create a 
permanently repressive chromatin state at targeted promoters.
To test our ability to dynamically control expression of essential genes on a larger scale, we 
cloned a sublibrary targeting 426 manually curated genes (10 sgRNAs/TSS or 4,923 
targeting sgRNAs plus 750 non-targeting controls). This library was transduced into K562 
cells stably expressing our inducible KRAB-dCas9 fusion protein, and cell growth effects 
were then evaluated in the presence and absence of doxycycline. Only 4 sgRNAs were 
depleted strongly in the absence of doxycycline; however, with induction of KRAB-dCas9, 
many sgRNAs were strongly depleted (Figure 5E). Negative control sgRNAs again 
produced a narrow distribution of phenotypes with little correlation between biological 
replicates with or without doxycycline. Additionally, we found no evidence that targeted 
KRAB-dCas9 generally impedes cell growth (Figure 5F). Taken together, these results 
demonstrate CRISPRi is non-toxic, inducible and reversible.
A Genome-Scale CRISPRi Screen Reveals Pathways and Complexes that Govern 
Response to Cholera and Diphtheria Toxin
To test the performance of our CRISPRi approach for detecting genes controlling a more 
complex cellular phenotype, we performed a genome-scale CRISPRi screen for genes that 
modulate sensitivity to a chimeric toxin composed of the diphtheria toxin catalytic A subunit 
covalently linked to cholera toxin (CTx-DTA, Figure 6A). This chimera had been previously 
developed to provide a growth readout for cholera intoxication (Guimaraes et al., 2011). 
Some aspects of both cholera and diphtheria toxin entry and toxicity are well characterized 
but open questions remain. The cell surface receptor for cholera toxin is the GM1a 
ganglioside (Van Ness et al., 1980). After endocytosis, the toxin traffics via the Golgi to the 
endoplasmic reticulum (ER), from which it retro-translocates into the cytosol, possibly 
through the ER-associated degradation (ERAD) machinery. Once in the cytosol, the DTA 
moiety ADP-ribosylates the diphthamide residue in Elongation Factor 2, halting translation 
and killing the cell (Figure 6A).
Gilbert et al. Page 9
Cell. Author manuscript; available in PMC 2015 October 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
K562 cells expressing the CRISPRi sgRNA library and dCas9-KRAB were either grown 
under standard conditions or treated with several pulses of CTx-DTA over the course of 10 
days. We observed highly correlated enrichment and depletion of many sgRNAs between 
replicates, indicating that CRISPRi can identify genes that modulate both resistance and 
sensitivity to a selective pressure (Table S2).
We ranked genes by the average phenotype of their three strongest sgRNAs (Table S3, 
Figure 6B, and Figure S6). GSEA revealed that KEGG pathways enriched for top protective 
hit genes were “Infection with Vibrio cholerae” and “Glycosphingolipid biosynthesis, 
ganglio-series” (Figure S7B), while gene sets for top sensitizing genes included “ribosome” 
and “proteasome” (Figure S7B). Since the diphtheria toxin catalytic subunit inhibits 
translation, depletion of the ribosome can be expected to sensitize cells to the toxin. 
Disruption of the proteasome also sensitizes cells to CTx-DTA, suggesting that the cytosolic 
toxin is a substrate for proteasomal degradation. Taken together, the unbiased GSEA 
analysis provides support for the high specificity in hit gene identification by our CRISPRi 
approach.
We further defined the 50 hits with the strongest protective effect and the 50 hits with the 
strongest sensitizing effect as “top hits” (all of these are far outside of the range seen with 
otherwise matched negative control sgRNAs). We characterized these genes by assigning 
them to cellular pathways and protein complexes according to their previously characterized 
roles (Figure 6B and Figure S6). Our CRISPRi screen identified a protective effect of 
knockdown for all top hits recovered in the previously published haploid mutagenesis screen 
(white stars in Figure 6B). The two top pathways identified by haploid mutagenesis as 
modulating cellular sensitivity to CTx-DTA are the diphthamide biosynthetic pathway 
(required to generate eEF-2-diphthamide, the target of diphtheria toxin) and the ganglioside 
biosynthetic pathway (required to produce GM1a, the cell-surface receptor for cholera 
toxin). Our screen also identified many additional core components of each pathway. While 
knockdown of all hits in the diphthamide biosynthesis pathway had a protective effect, the 
results for ganglioside biosynthesis genes showed a more complex pattern: knockdown of 
enzymes involved in the production of GM1a were protective, whereas knockdown of 
enzymes that catalyze the production of other gangliosides (including GM1b) was 
sensitizing. These results provide genetic confirmation that GM1a is the relevant cell-
surface receptor for CTx-DTA and more broadly illustrate the value of being able to reliably 
detect both sensitizing and protective genes to dissect biological pathways.
Many of the top hits are components of cellular pathways and protein complexes previously 
identified in experiments to be important for retrograde trafficking and retro-translocation of 
other toxins such as ricin and Shiga toxin (Bassik et al., 2013; Smith et al., 2009). Retro-
translocation of the catalytic chain of CTx has been proposed to be mediated by the ER-
associated degradation (ERAD) pathway, although this pathway was not identified in 
previous genetic screens. Consistent with this proposed role for the ERAD machinery, 
knockdown of members of the ERAD E3 ubiquitin ligase complex, SYVN1 (encoding Hrd1) 
and SEL1L (the mammalian homolog of yeast Hrd3) rendered cells resistant to CTx-DTA. 
Factors that mediate cytosolic degradation of ERAD substrates (in particular UBXN4, also 
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known as UBXD2 or erasin, and the proteasome) appeared as sensitizing hits, suggesting 
that they may reduce cytosolic levels of the toxin’s catalytic subunit in WT cells.
To validate the suggested role of the identified ERAD factors in toxin retro-translocation 
from the ER to the cytosol, we quantified the amount of CTx chains in the cytosol and 
membrane fractions. As expected, SEL1L knockdown resulted in a dramatic reduction of 
cytosolic CTx-A1, whereas levels in the membrane fraction were much less affected (Figure 
7A–C). By contrast, knockdown of B4GALNT1, an enzyme required for the synthesis of the 
CTx receptor GM1a, resulted in a nearly complete absence of CTx chains from both the 
cytosolic and the membrane fraction (Figure 7A–C).
An open question in CTx biology is how the toxin traverses the Golgi network (Wernick et 
al., 2010). Our screen revealed that COG and GARP complexes, which tether late 
endosomes to the trans-Golgi network or modulate intra-Golgi retrograde transport 
(Bonifacino and Rojas, 2006) are critical host factors for CTx-DTA. These and other 
complexes and pathways we identify here (Figure 6B), including several involved in RNA 
processing, had not previously been linked to cholera toxin biology, highlighting the 
potential of CRISPRi as a discovery platform. Importantly, many top hits—even those not 
previously implicated in cholera or diphtheria pathogenesis—were tightly clustered in well-
defined protein complexes and pathways. For several of these, the vast majority of 
components were hits, suggesting that CRISPRi screens can approach saturation.
Potent Phenotypes and Knockdown Levels Achieved by the Genome-Scale CRISPRi 
Library
To validate the results from this screen, we re-tested sgRNAs that putatively modulate 
cellular response to CTx-DTA in mechanistically diverse ways. For each sgRNA, we 
quantified both the ricin phenotypes as well as the change in abundance of the targeted 
transcript by qPCR. Our re-test experiments were highly correlated with data from the 
primary screen (Figure 7D). In our validation experiments for the tiling ricin screen and the 
genome-scale CTx-DTA screen, the activities of 71 out of 72 sgRNAs were robustly 
confirmed and were highly correlated (R2=0.879) with the results obtained in the primary 
screen. Finally, analysis of mRNA levels by qPCR data showed robust repression, with 
~80–99% knockdown for each sgRNA and at least 90% for every gene (Figure 7E).
A Genome-Scale CRISPRa Screen of Cholera-diphtheria Toxin Complements and Extends 
CRISPRi Results
To further explore the biological insights gained from CRISPRa screening, we performed a 
genome scale CRISPRa screen for genes that modulate sensitivity to CTx-DTA (Table S2–
3). As with the CRISPRi screen, GSEA revealed the specificity of the detected hits (Figure 
S7B). For some of the top hits, CRISPR-mediated transcriptional activation and repression 
caused opposite phenotypes (e.g. enzymes in ganglioside biosynthesis, Figure 6C), similar to 
what we observed for genes controlling ricin sensitivity (Figure 3C).
CRISPRa also revealed additional and highly complementary information as illustrated by 
analysis of glycosphingolipid biosynthesis pathways. Induction of enzymes in the neolacto 
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branch of sphingolipid biosynthesis protected cells from CTx-DTA (Figure 6C and Figure 
S7A,C). This pathway is a parallel branch to the ganglioside branch, which produces the 
CTx-DTA receptor GM1a. Our findings suggest that upregulation of the neolacto branch 
diverts the common precursor lactosylceramide away from the ganglioside branch. 
Similarly, upregulation of the sulfatide-generating enzyme GAL3ST1 has a protective effect, 
presumably by diverting ceramide from the sphingolipid to the cerebroside pathway (Figure 
6C). These results highlight the capacity of CRISPRa to complement CRISPRi by querying 
the consequences of upregulating pathways that may otherwise be inactive.
Effective Knockdown of non-coding RNAs
Finally, we investigated whether CRISPRi was able to repress the transcription of long non-
coding RNAs (lncRNAs), a class of transcripts that have been difficult to systematically 
perturb by other methods (Bassett et al., 2014). Using our CRISPRi library design algorithm, 
we selected and cloned up to three sgRNAs each targeting six characterized lncRNAs 
(GAS5, H19, MALAT1, NEAT1, TERC, XIST) (Geisler and Coller, 2013) with good evidence 
of expression in K562 cells. We transduced the sgRNAs into cells expressing dCas9-KRAB 
and quantified the amount of transcript knockdown by qPCR. We achieved >80% 
knockdown for all but one of the lncRNA genes tested (Figure 7F). Overall, more than 50% 
of the sgRNAs yielded >85% knockdown. We confirmed the strong repression of XIST by 
RNA fluorescence in situ hybridization (FISH) and observed no residual expression along 
the X chromosome (Figure 7G). These results demonstrate that CRISPRi can effectively 
repress lncRNA expression, enabling future systematic studies of non-coding gene function.
DISCUSSION
Here, we establish CRISPRi and CRISPRa as robust tools for systematically manipulating 
transcription of endogenous genes in human cells. We demonstrate that CRISPRi/a can be 
used to rapidly screen for both loss-of-function and gain-of-function phenotypes in a pooled 
format. We identify both known and unexpected genes that control growth of K562 cells or 
that modulate sensitivity to a toxin (CTx-DTA). We also show that we can use CRISPRi/a to 
create allelic series of gene expression, spanning a broad range from ~100-fold repression to 
~10-fold induction, allowing us to define how the abundance of a protein or transcript 
relates to its function.
A key feature of CRISPRi is the low incidence of off-target effects, as evidenced by the 
near-absence of activity for three large and distinct classes of negative control sgRNAs in 
our genome-scale CRISPRi library. This feature simplifies validation and interpretation of 
screening results. The observed specificity likely stems from two distinct properties of our 
system. First, CRISPRi/a complexes bound outside a narrow window around the TSS 
largely fail to modulate transcription; this dramatically shrinks the sequence space across the 
genome where off-target binding could produce significant off-target activity. Second, 
CRISPRi activity is highly sensitive to mismatches between the sgRNA and target DNA, 
suggesting that off-target binding of dCas9 observed in ChIP-seq experiments is too 
transient to impact transcription (Duan et al., 2014; Kuscu et al., 2014; Wu et al., 2014).
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CRISPRa screening provides a new approach for exploring the diversity of transcripts across 
complex genomes. Gene activation has been used to dissect the limiting component of a 
biochemical process, identify the molecular target of a drug, or activate key rate-limiting 
steps in a pathway (Davis et al., 1987; Rine et al., 1983). Recently, a combinatorial cDNA 
overexpression screen identified genes that, when co-expressed, reprogram fibroblasts into 
pluripotent stem cells (Takahashi and Yamanaka, 2006). CRISPRa should greatly accelerate 
similar searches for combinations of factors with emergent properties. In addition, CRISPRa 
will likely provide insight into cellular pathways where redundancy hampers loss-of-
function genetic approaches. CRISPRa will also enable the exploration of cellular states in 
which otherwise inactive pathways are induced, and thereby reveal functional coupling 
within complex cellular networks and suggest potential therapeutic strategies.
Our ability to control transcription with high specificity simplifies the analysis and 
validation of high-throughput screening data. The genome-scale CRISPRi and CRISPRa 
libraries described here contain 10 sgRNAs per TSS. The resulting library size allows each 
to be screened in a population of 200 million cells, which can be easily grown in a single 
spinner flask. Furthermore, the observed high specificity and an improved understanding of 
rules governing sgRNA activity should enable us to create even more compact sgRNA 
libraries. Additionally, an sgRNA library designed to activate or repress a broader range of 
transcripts in the human genome could reveal the function of many non-canonical RNAs 
encoded in the human genome. As most non-coding transcripts are nuclear and lack an open 
reading frame, methods that directly modulate transcription are optimally suited for 
interrogating the function of these RNAs (Derrien et al., 2012).
Systematic genetic interaction (GI) maps are powerful tools for revealing gene functions 
within pathways or complexes (Bassik et al., 2013; Boone et al., 2007; Costanzo et al., 
2010). A CRISPRa GI map or a combined CRISPRi/a GI map could yield rich novel 
biology and help elucidate how networks of proteins dictate cellular function. More 
generally, quantitative methods of turning on and off one or multiple transcripts represent a 
critical tool for understanding how expression of the genes encoded in our genomes controls 
cell function and fate.
EXPERIMENTAL PROCEDURES
CRISPRi/a Libraries
Tiling libraries—sgRNAs were designed targeting 49 genes (see Figure 1E) previously 
identified in shRNA screens as having ricin resistance phenotype. All possible sgRNAs 
within a 10kb window around the gene TSS and meeting certain criteria were included (see 
Extended Experimental Procedures). Negative controls were designed based on scrambled 
sequences from these 10kb windows and filtered by the same criteria as targeting sgRNAs.
Genome-scale CRISPRi/a libraries—Genes were selected from the entire set of protein 
coding genes, although a subset of genes with a RPKM of 0 in a K562 cell RNA-seq 
expression data set were excluded. sgRNAs conforming to rules including low predicted off-
targets and minimal length (see Figure S2 and Extended Experimental Procedures) were 
selected from a window of −50 to +300bp (CRISPRi) or −400 to −50bp (CRISPRa) with 
Gilbert et al. Page 13
Cell. Author manuscript; available in PMC 2015 October 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
respect to the TSS. Negative controls we designed in the same way based on scrambled 
sequence derived from the same window of several hundred genes.
Library Cloning—Oligonucleotides encoding sgRNAs designed as described above were 
synthesized as pooled libraries. These were then cloned into lentiviral vectors for expression 
from a U6 promoter (see Extended Experimental Procedures).
Cell Line Construction
For constitutive and inducible CRISPRi screens, polyclonal cells expressing dCas9/KRAB 
fusion proteins driven from an SFFV or TRE3G promoter, respectively, were generated by 
viral transduction. For CRISPRa screens, a clonal cell line expressing dCas9-GCNx10 and a 
scFV-sfGFP-VP64 fusion was generated (See Extended Experimental Procedures).
Growth and Toxin Screens
Cells were grown at minimum library coverage of 1,000 for tiling screens and 3,750 for 
genome-scale screens. For growth screens cells were grown in spinner flasks and harvested 
at 0 and 10 days after puromycin selection. For toxin screens, cells were treated with pulses 
of ricin or CTx-DTA (Bassik et al., 2013; Guimaraes et al., 2011) and harvested when 
sufficient selective pressure relative to untreated cells had been applied. Briefly, DNA was 
isolated, the cassette encoding the sgRNA was amplified by PCR, and relative sgRNA 
abundance was determined by next generation sequencing as previously described (Bassik et 
al., 2013; Kampmann et al., 2014).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
CRISPRi and CRISPRa provide complementary information for mapping complex 
pathways
CRISPRi/a expression series (up to ~1000 fold) reveal how gene dose controls 
function
CRISPRi provides strong (typically 90–99%) knockdown with minimal off-target 
effects
Genome-scale screens elucidate pathways controlling cholera/diphtheria toxicity
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Figure 1. A Tiling sgRNA Screen Defines Rules for CRISPRi Activity at Endogenous Genes in 
Human Cells
(A) Massively parallel determination of growth or toxin resistance phenotypes caused by 
sgRNAs in mammalian cells expressing dCas9 or dCas9 fusion constructs. (B) UCSC tracks 
showing the genomic organization, GC content, and repetitive elements around the TSS of a 
representative gene, VPS54, across a 10kb window targeted by the tiling sgRNA library. 
sgRNA ricin resistance phenotypes (as z-scores, see Figure S1 and Experimental 
Procedures) in dCas9 and dCas9-KRAB expressing K562 cells are depicted in black on the 
top and bottom, respectively. See also Figure S2A for more examples. (C) Sliding-window 
analysis of all 49 genes targeted in a tiling sgRNA library. Green line: median sgRNA 
activity in a defined window for all genes. Orange region: observed average window of 
maximum CRISPRi activity. Data displayed as a phenotype signed z-score, excluding all 
guides longer than 22bp. (D) CRISPRi activity for all 49 genes in defined windows relative 
to the TSS of each gene. (E) Ricin resistance phenotypes, comparing CRISPRi sgRNAs 
selected by our rules to RNAi, for genes previously established to cause ricin resistance 
phenotypes when knocked down by RNAi. Mean phenotype-signed z-score for 10 
subsampled sgRNAs or shRNAs. See also Figure S2F.
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Figure 2. CRISPRi Activity is Highly Sensitive to Mismatches Between the sgRNA and DNA 
sequence
On- and off-target activity of dCas9, dCas9-KRAB and Cas9 for sgRNAs with a varying 
number and position of mismatches. Off-target activity of sgRNAs with mismatches is 
displayed as percent of the on-target activity for the corresponding sgRNA without 
mismatches. Asterisk indicates sgRNAs with 3, 4, or 5 mismatches randomly distributed 
across region 3 of the sgRNA sequence. Data is displayed for each mismatch position as the 
mean of all sgRNAs with that mismatch; see Figure S3 for individual sgRNA activities. 
sgRNAs were included in the analysis only if the fully matched guide was highly active 
(phenotype-signed z-score ≥ 4); N=5 for dCas9, N=11 for dCas9-KRAB, and N=10 for 
Cas9.
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Figure 3. A Tiling sgRNA Screen Defines Rules for CRISPRa Activity at Endogenous Genes in 
Human Cells
(A) A schematic of the dCas9-SunTag + scFV−VP64 + sgRNA system for CRISPRa. (B) 
Activity of sgRNAs in K562 cells stably expressing each component of CRISPRa, as a 
function of the distance of the sgRNA site to the TSS of the targeted gene (Phenotype-
signed z-scores; therefore, negative values represent opposite results than from knockdown). 
Top, sgRNAs targeting VPS54; Bottom, sliding-window analysis of all 49 genes targeted by 
our tiling library in green. Green line, median activity; orange, window of maximal activity. 
Guides longer than 22bp were excluded. See also Figure S4. (C) CRISPRa phenotypes and 
CRISPRi (dCas9-KRAB) phenotypes are anti-correlated for select genes. For each gene, a 
p-value is calculated using CRISPRi/a sgRNA activity relative to a negative control 
distribution for 24 sub-sampled sgRNAs. (D) CRISPRi knockdown and CRISPRa activation 
of the same gene can have opposing effects on ricin resistance in both primary screens and 
single sgRNA validation experiments (mean ± standard deviation of 3 replicates). (E) 
Modulation of expression levels for 3 genes by CRISPRi and CRISPRa as quantified by 
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qPCR plotted against the ricin resistance phenotype (mean ± standard deviation of 3 
replicates) measured for each sgRNA.
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Figure 4. Genome-Scale CRISPRi and CRISPRa Screens Reveal Genes Controlling Cell Growth
(A) sgRNA phenotypes from a genome-scale CRISPRi screen for growth in human K562 
cells (black). Three classes of negative control sgRNAs are color-coded: non-targeting 
sgRNAs (grey), sgRNAs targeting Y-chromosomal genes (green) and sgRNAs targeting 
olfactory genes (orange). (B) Co-expression of sgRNAs and dCas9-KRAB or dCas9-SunTag 
+ scFV−VP64 is not toxic in K562 cell lines over 16 days. (C) Gene set enrichment analysis 
(GSEA) for hits from the CRISPRi screen. A histogram of gene distribution is shown under 
the GSEA curve. (D) CRISPRi versus CRISPRa gene phenotypes for genome-scale growth 
screens (black). For the 50 genes in the CRISPRa screen with the most negative growth 
phenotype, each gene was annotated and labeled based on evidence of activity as a tumor 
suppressor (orange), developmental transcription factor (green), or in regulation of the 
centrosome (purple). Two additional CRISPRi hit genes that are discussed in the text are 
labeled in red. See Table S4 for annotations and references. (E) GSEA for hits from the 
CRISPRa growth screen. A histogram of gene distribution is shown under the GSEA curve.
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Figure 5. CRISPRi Gene Silencing is Inducible, Reversible, and Non-Toxic
(A) Expression construct encoding an inducible KRAB-dCas9 fusion protein. (B) Western 
blot analysis of inducible KRAB-dCas9 in the absence, presence, and after washout of 
doxycycline. (C) Relative RAB1A expression levels (as quantified by qPCR) in inducible 
CRISPRi K562 cells transduced with RAB1A-targeting sgRNAs in the absence, presence, 
and after washout of doxycycline. Mean ± standard error of technical replicates (N=2) 
normalized to control cells (assayed in the presence of doxycycline) from the day 2 time 
point. (D) Competitive growth assays performed with inducible CRISPRi K562 cells 
transduced with the indicated sgRNAs in the presence and absence of doxycycline. Data is 
represented as the mean ± standard deviation of replicates (N=3). See also Figure S5G. (E) 
A CRISPRi sublibrary screen for effects on cell growth was performed with inducible 
CRISPRi K562 cells in the presence and absence of doxycycline. (F) Cumulative growth 
curves from the sublibrary screen represented in (E) show no bulk changes to growth caused 
by induction of KRAB-dCas9. Mean ± standard deviation of replicate infections each 
screened in duplicate.
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Figure 6. Genome-Scale CRISPRi and CRISPRa Screens Reveal Known and New Pathways and 
Complexes Governing the Response to a Cholera-Diphtheria Fusion Toxin (CTx-DTA)
(A) Model for CTx-DTA binding, retrograde trafficking, retro-translocation and cellular 
toxicity. (B) Overview of top hit genes detected by the CTx-DTA screen. Dark red and blue 
circles: Top 50 sensitizing and protective hits, respectively. Light red and blue circles: 
further hits that fall into the same protein complexes or pathways as top 50 hits. Circle area 
is proportional to phenotype strength. White stars denote genes identified in a previous 
haploid mutagenesis screen (Guimaraes et al., 2011). See also Figure S6 for hit gene names. 
(C) CRISPRi and CRISPRa hits in sphingolipid metabolism. Display as in (B), except that 
the left and right sides of each circle represent the phenotypes in the CRISPRi and CRISPRa 
screens, respectively.
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Figure 7. CRISPRi Strongly Represses Gene Expression of Both Protein-Coding and Non-
Coding Genes, Resulting in Reproducible Phenotypes
(A–C) Cells expressing a negative control sgRNA or an sgRNA targeting SEL1L or 
B4GALNT1 were incubated with cholera toxin and fractionated to quantify cholera toxin 
present in the cytosolic and membrane fractions by Western blot. B4GALNT1 repression 
blocks toxin uptake whereas SEL1L repression prevents toxin retro-translocation from the 
membrane fraction to the cytosol. (D) Validation of CTx-DTA screen phenotypes with 
single sgRNA re-test experiments. Data is represented as the mean ± standard deviation of 
replicates (N=3). (E) CRISPRi knockdown of 13 hit genes (28 sgRNAs; same sgRNAs as 
7D) identified in the CTx-DTA screen was quantified by qPCR. The gray shaded region 
denotes sgRNAs showing at least 90% knockdown for each gene. (F) CRISPRi knockdown 
of 6 lncRNA genes was quantified by qPCR. 2–3 sgRNAs computationally predicted to 
target each gene were cloned and transduced into K562 cells expressing dCas9-KRAB. (G) 
K562 cells expressing dCas9-KRAB were transduced with either a non-targeting sgRNA or 
an sgRNA targeting the XIST locus (sgXIST-1). The cells were then stained with DAPI and 
an RNA FISH probe for the XIST transcript. 200 non-apoptotic interphase cells in each 
condition were scored for XIST RNA coating. XIST is undetectable in cells transduced with 
sgXIST-1. Scale bar represents 5μm.
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